Abbott Laboratories provided earnings guidance for the full-year 2023. For the year, the company expects diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2.0 billion.